Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
venetoclax
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C22H25ClN6O3S
|
| gptkbp:clinicalTrials |
gptkb:BOVEN_trial
gptkb:MURANO_trial Phase 3 CAVALRY trial CLL14 trial VENICE trial |
| gptkbp:contraindication |
anemia
headache muscle pain cough fever vomiting constipation infections thrombocytopenia severe hepatic impairment hypersensitivity to venetoclax tumor lysis syndrome |
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
strong CYP3A inducers
strong CYP3A inhibitors bioavailability 70% half-life 26 hours metabolized by CYP3A |
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Venclexta
|
| gptkbp:impact |
based on clinical response
|
| gptkbp:is_monitored_by |
renal function
liver function complete blood counts |
| gptkbp:isATypeOf |
1257044-40-8
|
| gptkbp:lastProduced |
2016
|
| gptkbp:mandates |
relapsed_or_refractory_CLL
treatment_of_AML |
| gptkbp:manufacturer |
AbbVie
|
| gptkbp:marketingStrategy |
gptkb:Health_Canada
gptkb:European_Medicines_Agency |
| gptkbp:operates_in |
L01XX40
|
| gptkbp:packaging |
bottles of 30 tablets
|
| gptkbp:route |
oral
|
| gptkbp:sells |
gptkb:Venclexta
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea neutropenia |
| gptkbp:storage |
store at 20-25°C
|
| gptkbp:triggerType |
BCL-2 inhibitor
|
| gptkbp:usedFor |
gptkb:acute_myeloid_leukemia
chronic lymphocytic leukemia |